Breaking News, Financial News

Sanofi 4Q Revenues up 2%

Dupixent and newly launched RSV vaccine Beyfortus help offset 74% decline in Aubagio sales due to generic competition.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi 4Q Revenues: €10.9 billion (+2%) 4Q Loss: €555 million (-118%) FY Revenues: €43.1 billion (flat) FY Earnings: €5.4 billion (-36%) Comments: Specialty Care sales were up 13.7% in the quarter driven by Dupixent with sales of €2.99 billion, up 31%, and ALTUVIIIO launches, offsetting competition from generics of Aubagio in all key markets. Aubagio sales were down 74% to €121 million in the quarter. Myozyme sales were down 20% to €160 million. Nexviazyme sales were up 115% to €131 million...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters